BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 30376985)

  • 21. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research progress of CRISPR-Cas9 system for gene therapy].
    Zhan C; Xia X
    Sheng Wu Gong Cheng Xue Bao; 2016 Jul; 32(7):861-869. PubMed ID: 29019208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in Therapeutic Genome Editing in China.
    Yang Y; Wang Q; Li Q; Men K; He Z; Deng H; Ji W; Wei Y
    Hum Gene Ther; 2018 Feb; 29(2):136-145. PubMed ID: 29446996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
    Harris E
    JAMA; 2024 Jan; 331(4):280. PubMed ID: 38170544
    [No Abstract]   [Full Text] [Related]  

  • 25. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
    Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
    Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The promise and challenge of therapeutic genome editing.
    Doudna JA
    Nature; 2020 Feb; 578(7794):229-236. PubMed ID: 32051598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new era of gene editing for the treatment of human diseases.
    Kc M; Steer CJ
    Swiss Med Wkly; 2019 Jan; 149():w20021. PubMed ID: 30685869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease.
    Limanskiy V; Vyas A; Chaturvedi LS; Vyas D
    World J Gastroenterol; 2019 May; 25(18):2177-2187. PubMed ID: 31143069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment by CRISPR-Cas9 Gene Editing - A Proof of Principle.
    Malech HL
    N Engl J Med; 2021 Jan; 384(3):286-287. PubMed ID: 33471982
    [No Abstract]   [Full Text] [Related]  

  • 30. The Cas9 Hammer-and Sickle: A Challenge for Genome Editors.
    Urnov FD
    CRISPR J; 2021 Feb; 4(1):6-13. PubMed ID: 33616446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of Fetal Hemoglobin by Gene Therapy.
    Walters MC
    N Engl J Med; 2021 Jan; 384(3):284-285. PubMed ID: 33471981
    [No Abstract]   [Full Text] [Related]  

  • 34. The Future of Genome Editing.
    Cell; 2018 May; 173(6):1311-1313. PubMed ID: 29856947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR editing in biological and biomedical investigation.
    Huang J; Wang Y; Zhao J
    J Cell Physiol; 2018 May; 233(5):3875-3891. PubMed ID: 28786481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress and Application of CRISPR/Cas Technology in Biological and Biomedical Investigation.
    Lin J; Zhou Y; Liu J; Chen J; Chen W; Zhao S; Wu Z; Wu N
    J Cell Biochem; 2017 Oct; 118(10):3061-3071. PubMed ID: 28590031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discontinued CRISPR gene therapy for sickle-cell disease improves symptoms.
    Carvalho T
    Nat Med; 2023 Nov; 29(11):2669-2670. PubMed ID: 37783810
    [No Abstract]   [Full Text] [Related]  

  • 38. CRISPR/Cas9 system and its applications in human hematopoietic cells.
    Hu X
    Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives of Sickle Cell Disease Stakeholders on Heritable Genome Editing.
    Hollister BM; Gatter MC; Abdallah KE; Armsby AJ; Buscetta AJ; Byeon YJJ; Cooper KE; Desine S; Persaud A; Ormond KE; Bonham VL
    CRISPR J; 2019 Dec; 2(6):441-449. PubMed ID: 31742431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.